MX355303B - Compuestos novedosos. - Google Patents

Compuestos novedosos.

Info

Publication number
MX355303B
MX355303B MX2014014274A MX2014014274A MX355303B MX 355303 B MX355303 B MX 355303B MX 2014014274 A MX2014014274 A MX 2014014274A MX 2014014274 A MX2014014274 A MX 2014014274A MX 355303 B MX355303 B MX 355303B
Authority
MX
Mexico
Prior art keywords
novel compounds
derivatives
intreating
diseases
modulation
Prior art date
Application number
MX2014014274A
Other languages
English (en)
Other versions
MX2014014274A (es
Inventor
David R Witty
David T Macpherson
Gerard M P Giblin
Steven J Stanway
Original Assignee
Convergence Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals filed Critical Convergence Pharmaceuticals
Publication of MX2014014274A publication Critical patent/MX2014014274A/es
Publication of MX355303B publication Critical patent/MX355303B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a derivados de espiro, al uso de dichos derivados en el tratamiento de enfermedades y condiciones mediadas por la modulación de canales de sodio controlados por voltaje, a composiciones que contienen dichos derivados y procedimientos para su preparación.
MX2014014274A 2012-05-22 2013-05-22 Compuestos novedosos. MX355303B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261650325P 2012-05-22 2012-05-22
GB201209015A GB201209015D0 (en) 2012-05-22 2012-05-22 Novel compounds
US201361773710P 2013-03-06 2013-03-06
PCT/GB2013/051335 WO2013175205A1 (en) 2012-05-22 2013-05-22 Novel Compounds

Publications (2)

Publication Number Publication Date
MX2014014274A MX2014014274A (es) 2015-06-17
MX355303B true MX355303B (es) 2018-04-12

Family

ID=46546493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014274A MX355303B (es) 2012-05-22 2013-05-22 Compuestos novedosos.

Country Status (28)

Country Link
US (7) US9309254B2 (es)
EP (3) EP2861602B1 (es)
JP (3) JP2015517562A (es)
KR (2) KR102161101B1 (es)
CN (2) CN107344942B (es)
AU (3) AU2013265001B2 (es)
BR (1) BR112014029280B1 (es)
CA (1) CA2873956C (es)
CY (2) CY1118274T1 (es)
DK (2) DK3106464T3 (es)
EA (1) EA025579B1 (es)
ES (3) ES2602193T3 (es)
GB (1) GB201209015D0 (es)
HK (1) HK1209423A1 (es)
HR (2) HRP20161349T1 (es)
HU (2) HUE031664T2 (es)
IL (4) IL235805A (es)
IN (1) IN2014MN02393A (es)
LT (2) LT3106464T (es)
MX (1) MX355303B (es)
PL (2) PL2861602T3 (es)
PT (2) PT2861602T (es)
RS (2) RS60368B1 (es)
SG (2) SG11201407755UA (es)
SI (2) SI2861602T1 (es)
SM (1) SMT201600421B (es)
WO (2) WO2013175205A1 (es)
ZA (1) ZA201408253B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
CA3074923A1 (en) * 2017-09-28 2019-04-04 Biogen Inc. Novel salts
MX2020003821A (es) 2017-10-10 2023-01-12 Biogen Inc Proceso de elaboración de espiroderivados.
WO2022133097A1 (en) * 2020-12-17 2022-06-23 Biogen Ma Inc. Synthesis of compounds that modulate use-dependent voltage-gated sodium channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005293A2 (en) * 2002-07-05 2004-01-15 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
GB0520578D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
US8143306B2 (en) 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
WO2007042250A1 (en) 2005-10-10 2007-04-19 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
JP2009511599A (ja) * 2005-10-12 2009-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体
US7998959B2 (en) * 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
CL2007002953A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
CN101522685A (zh) * 2006-10-12 2009-09-02 泽农医药公司 三环螺-吲哚酮衍生物及其作为治疗剂的用途
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8759542B2 (en) 2009-09-14 2014-06-24 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide derivatives
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
TWI625046B (zh) * 2012-03-21 2018-05-21 內數位專利控股公司 在無線網路中行動站贊助方法及裝置
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
GB201209670D0 (en) 2012-05-31 2012-07-18 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
GB201209015D0 (en) 2012-07-04
WO2013175206A1 (en) 2013-11-28
AU2013265001B2 (en) 2016-12-01
EP3106464A1 (en) 2016-12-21
EA025579B1 (ru) 2017-01-30
PT2861602T (pt) 2016-11-14
CA2873956C (en) 2021-03-23
PL3106464T3 (pl) 2020-11-16
IL252033B (en) 2019-12-31
US20170304303A1 (en) 2017-10-26
EA201492169A1 (ru) 2015-04-30
RS60368B1 (sr) 2020-07-31
ES2602193T3 (es) 2017-02-20
AU2013265001A1 (en) 2014-12-18
JP6169687B2 (ja) 2017-07-26
CN104640867B (zh) 2017-07-21
BR112014029280B1 (pt) 2022-10-04
US20200289508A1 (en) 2020-09-17
CN107344942A (zh) 2017-11-14
US10010551B2 (en) 2018-07-03
ES2782088T3 (es) 2020-09-10
EP2861594B1 (en) 2016-08-24
IL271330B (en) 2021-02-28
AU2018201653B2 (en) 2019-05-02
SG10201703527WA (en) 2017-06-29
RS55415B1 (sr) 2017-04-28
US20150119404A1 (en) 2015-04-30
US10485801B2 (en) 2019-11-26
SMT201600421B (it) 2017-01-10
US20160184306A1 (en) 2016-06-30
HRP20161349T1 (hr) 2017-01-27
US20180360833A1 (en) 2018-12-20
IL271330A (en) 2020-01-30
US9309254B2 (en) 2016-04-12
PL2861602T3 (pl) 2017-05-31
SI3106464T1 (sl) 2020-12-31
HUE049445T2 (hu) 2020-09-28
HK1209423A1 (en) 2016-04-01
US9376445B2 (en) 2016-06-28
DK3106464T3 (da) 2020-03-23
HRP20200580T1 (hr) 2020-10-02
US20160263115A1 (en) 2016-09-15
CN107344942B (zh) 2020-09-25
DK2861602T3 (en) 2016-11-28
WO2013175205A1 (en) 2013-11-28
PT3106464T (pt) 2020-04-03
ES2602308T3 (es) 2017-02-20
ZA201408253B (en) 2015-12-23
KR102161101B1 (ko) 2020-10-20
AU2018201653A1 (en) 2018-03-29
SI2861602T1 (sl) 2017-03-31
IL280595A (en) 2021-03-25
JP2015517562A (ja) 2015-06-22
JP2017206534A (ja) 2017-11-24
US20150166551A1 (en) 2015-06-18
IL235805A0 (en) 2015-02-01
IN2014MN02393A (es) 2015-08-21
KR20200113027A (ko) 2020-10-05
IL252033A0 (en) 2017-06-29
JP6378404B2 (ja) 2018-08-22
CA2873956A1 (en) 2013-11-28
CY1118274T1 (el) 2017-06-28
JP2015517561A (ja) 2015-06-22
IL235805A (en) 2017-05-29
SG11201407755UA (en) 2014-12-30
MX2014014274A (es) 2015-06-17
HUE031664T2 (en) 2017-07-28
CY1123044T1 (el) 2021-10-29
AU2017201421B2 (en) 2017-12-07
EP2861602A1 (en) 2015-04-22
EP2861602B1 (en) 2016-08-10
US9737536B2 (en) 2017-08-22
EP2861594A1 (en) 2015-04-22
AU2017201421A1 (en) 2017-03-23
BR112014029280A2 (pt) 2017-06-27
EP3106464B1 (en) 2020-01-08
LT2861602T (lt) 2016-11-10
KR20150023401A (ko) 2015-03-05
LT3106464T (lt) 2020-04-10
CN104640867A (zh) 2015-05-20

Similar Documents

Publication Publication Date Title
MD20150091A2 (ro) Compuşi antivirali
CR20150370A (es) Compuestos antivirales
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
PH12015501289A1 (en) Novel benzimidazole derivatives as ep4 antagonists
PH12016500094A1 (en) Autotaxin inhibitors
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
PH12015500491A1 (en) C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
TW201240990A (en) Antiviral compounds
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
EA201290644A1 (ru) Блокаторы натриевых потенциал-зависимых каналов
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
WO2013165921A3 (en) Therapeutic use of chardonnay seed products
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
PH12014502032A1 (en) Treatment of brain cancer
WO2013108105A3 (en) Novel solvates of darunavir
IN2014MN01469A (es)
MX355303B (es) Compuestos novedosos.
WO2014172363A3 (en) Combretastatin analogs
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
MX338113B (es) Proceso para la preparacion de polisulfonato de sodio del 5,14-dihidrotetraazapentaceno e intermediarios de los mismos.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
IN2013MU01355A (es)

Legal Events

Date Code Title Description
FG Grant or registration